GVHD prophylaxis regimen

DRUG2 trials

Sponsors

Washington University School of Medicine, Shanxi Bethune Hospital

Conditions

Acute Myeloid LeukemiaBone Marrow Failure SyndromesHemoglobinopathiesImmunologic DisordersMetabolic DisordersNon-malignant DisordersSevere Sickle Cell Disease

Phase 1

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

RecruitingNCT03128996

Washington University School of MedicineBone Marrow Failure Syndromes, Hemoglobinopathies, Immunologic Disorders +3

Start: 2017-03-20End: 2033-04-01Target: 29Updated: 2026-05-29

Phase 2

Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study

RecruitingNCT07108530

Shanxi Bethune HospitalAcute Myeloid Leukemia

Start: 2025-08-06End: 2027-08-06Target: 50Updated: 2025-08-07

Related Papers

Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders

Blood2023-11-02

Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.

PubMed2020-08-2553 citations

Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)

Blood2019-11-131 citations